ASND Stock Overview
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ascendis Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$140.89 |
| 52 Week High | US$161.00 |
| 52 Week Low | US$66.03 |
| Beta | 0.51 |
| 1 Month Change | -3.08% |
| 3 Month Change | 6.72% |
| 1 Year Change | 69.70% |
| 3 Year Change | 6.86% |
| 5 Year Change | 26.44% |
| Change since IPO | 648.22% |
Recent News & Updates
Recent updates
Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S
Apr 05
Ascendis Pharma's Ambitious Vision 2030
Jan 11What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You
Dec 21Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?
Nov 10Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing
Oct 05Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?
Jun 27Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week
May 05Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?
Feb 18Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?
Sep 24Ascendis Pharma: TransCon CNP Data Coming Q4
Sep 15Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH
Aug 31Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa
Aug 11Ascendis Pharma: Institutional Buying Values Dutch Biotech Best-Now Cap-Gain Prospect
Aug 03Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money
Jun 10Ascendis Pharma: Biotech Bear Provides Attractive Entry Point
May 09Ascendis: Institutional Buying Activity Now Seen As Good Value By Market-Makers
Apr 29Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 51% Above Its Share Price
Feb 24Is Ascendis Pharma (NASDAQ:ASND) In A Good Position To Invest In Growth?
Jan 07Ascendis: Danish Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Dec 30Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 97% Above Its Share Price
Sep 24Ascendis Pharma: A Promising Platform And A Rich Valuation
Sep 10We're Hopeful That Ascendis Pharma (NASDAQ:ASND) Will Use Its Cash Wisely
Aug 12Best Biotech Stock (Now): Ascendis Pharma, Where Best = Capital Gain ODDS Next 3 Months
Jun 30Shareholder Returns
| ASND | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.7% | -4.7% | -3.7% |
| 1Y | 69.7% | -2.7% | 20.2% |
Return vs Industry: ASND exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: ASND exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| ASND volatility | |
|---|---|
| ASND Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ASND has not had significant price volatility in the past 3 months.
Volatility Over Time: ASND's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 879 | Jan Mikkelsen | ascendispharma.com |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Ascendis Pharma A/S Fundamentals Summary
| ASND fundamental statistics | |
|---|---|
| Market cap | US$8.05b |
| Earnings (TTM) | -US$512.45m |
| Revenue (TTM) | US$283.89m |
28.4x
P/S Ratio-15.7x
P/E RatioIs ASND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASND income statement (TTM) | |
|---|---|
| Revenue | €266.72m |
| Cost of Revenue | €44.40m |
| Gross Profit | €222.32m |
| Other Expenses | €703.77m |
| Earnings | -€481.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.43 |
| Gross Margin | 83.36% |
| Net Profit Margin | -180.51% |
| Debt/Equity Ratio | -374.4% |
How did ASND perform over the long term?
See historical performance and comparison